Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

James LaBelle to lead pediatric cancer, blood diseases programs at Chicagoland Children’s Health Alliance, UChicago Medicine

James LaBelle has been appointed the service line chief of Pediatric Cancer and Blood Diseases for the Chicagoland Children’s Health Alliance, a collaboration between the University of Chicago Medicine Comer Children’s Hospital, Advocate Children’s Hospital and Pediatrics at Endeavor Health.

October 23, 2026

Vol.52 No.39

In Brief

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

An investigational CAR T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma, according to a phase I clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

In Brief

10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

October 16, 2026

Vol.52 No.38

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

YOU MAY BE INTERESTED IN

James LaBelle to lead pediatric cancer, blood diseases programs at Chicagoland Children’s Health Alliance, UChicago Medicine

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Renew today!

Subscriber content

Never miss an issue!

Login